CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 1.9×, higher than 95% of its Biotechnology peers (median 0.07×)
- FinancialsAltman Z-Score 0.24: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
883.00MUSDvs all stocks (USD)
Revenue (TTM)
450.89MUSDvs all stocks (USD)
Profit Margin
-12.35%vs Biotechnology peers
Beta
0.6920xvs all stocks
52-Week Change
-39.25%vs all stocks
Market Capitalization
883.00MUSDvs all stocks (USD)
Enterprise Value
860.37MUSDvs all stocks (USD)
Forward P/E
11.40xvs Biotechnology peers
Price to Sales (TTM)
1.95xvs Biotechnology peers
Price to Book (MRQ)
5.70xvs Biotechnology peers
Enterprise to Revenue
1.91xvs Biotechnology peers
Enterprise to EBITDA
-26.80xvs Biotechnology peers
Gross Margin
95.24%vs Biotechnology peers
Profit Margin
-12.35%vs Biotechnology peers
Operating Margin
-10.28%vs Biotechnology peers
Return on Assets (TTM)
-4.25%vs Biotechnology peers
Return on Equity (TTM)
-38.61%vs Biotechnology peers
Revenue (TTM)
450.89MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.84USDUpdated Sep 26, 2026Quarterly Revenue Growth
23.80%vs Biotechnology peers
Gross Profit (TTM)
338.28MUSDvs all stocks (USD)
EBITDA (TTM)
-32.11MUSDvs all stocks (USD)
Net Income (TTM)
-55.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
23.77%vs Biotechnology peers
Operating Cash Flow (TTM)
-17.32MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
407.32MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
39.54MUSDFY2025 · Dec 31, 2025Gross Profit
367.78MUSDFY2025 · Dec 31, 2025Operating Income
-40.98MUSDvs all stocks (USD)
Pre-tax Income
-60.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
969.00KUSDFY2025 · Dec 31, 2025Net Income
-61.60MUSDFY2025 · Dec 31, 2025EBIT
-32.23MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.17MUSDFY2025 · Dec 31, 2025Research & Development
71.53MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
337.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
28.40MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
241.03MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
241.03MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-61.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-58.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-60.29MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
68.00MUSDFY2025 · Dec 31, 2025Income Tax Paid
485.00KUSDFY2025 · Dec 31, 2025Interest Paid
15.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-61.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.06MUSDFY2025 · Dec 31, 2025Stock-based Compensation
48.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.55MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.14MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.23MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-36.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.49MUSDFY2025 · Dec 31, 2025Purchase of Investments
-218.92MUSDFY2025 · Dec 31, 2025Sale of Investments
211.46MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.96MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
48.67MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
48.67MUSDFY2025 · Dec 31, 2025Shares Outstanding
249.15MSharesUpdated Sep 26, 2026Float Shares
210.66MSharesUpdated Sep 26, 2026Shares Short
25.60MSharesUpdated Sep 26, 2026Short Ratio
6.59daysvs all stocks
Short % of Shares Outstanding
10.13%vs all stocks
% Held by Insiders
3.17%vs all stocks
% Held by Institutions
73.22%vs all stocks
Total Cash (MRQ)
281.83MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.13USDUpdated Sep 26, 2026Total Debt (MRQ)
282.51MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.90xvs Biotechnology peers
Current Ratio (MRQ)
3.34xvs Biotechnology peers
Book Value per Share (MRQ)
0.5980USDUpdated Sep 26, 2026Total Assets
501.60MUSDvs all stocks (USD)
Total Current Assets
382.32MUSDFY2025 · Dec 31, 2025Total Liabilities
334.65MUSDFY2025 · Dec 31, 2025Total Non-current Assets
119.29MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
246.05MUSDFY2025 · Dec 31, 2025Total Current Liabilities
88.61MUSDFY2025 · Dec 31, 2025Cash
18.57MUSDFY2025 · Dec 31, 2025Cash Equivalents
49.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
68.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
196.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
71.85MUSDFY2025 · Dec 31, 2025Inventory
17.73MUSDFY2025 · Dec 31, 2025Accounts Payable
19.23MUSDFY2025 · Dec 31, 2025Short-term Debt
1.48MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.21MUSDFY2025 · Dec 31, 2025Other Current Liabilities
7.35MUSDFY2025 · Dec 31, 2025Long-term Debt
206.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
24.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-946.94MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
166.95MUSDvs all stocks (USD)
52-Week Low
3.33USDUpdated Sep 26, 202652-Week High
8.40USDUpdated Sep 26, 202652-Week Change
-39.25%vs all stocks
Beta
0.6920xvs all stocks
50-Day MA
4.16USDUpdated Sep 26, 2026200-Day MA
5.71USDUpdated Sep 26, 2026Avg 10-Day Volume
4.19MSharesUpdated Sep 26, 2026Avg 30-Day Volume
3.93MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.2300USDUpdated Sep 26, 2026Other Income / Expense
8.74MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.9×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.90Industry median: 0.07Industry P95: 0.93Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -0.12
Significant cash reserves alongside high leverageNotable
Cash (USD): 281,830,016Total Debt (USD): 282,507,008Debt-to-Equity: 1.90
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.34Altman Z-Score: 0.24
Financial Health
Altman Z-Score 0.24: distress zoneCritical
Altman Z-Score: 0.24
High structural barrier to entryNotable
Barrier to Entry: 11.24
Consistent revenue growth patternNotable
Growth Consistency Score: 0.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Badger Meter Inc.
2 interpretationsRevenue Growing With Receivables GrowingLow Fixed-Asset Share With Elevated Turnover
MiMedx Group, Inc.
2 interpretationsRevenue Growing With Receivables GrowingLow Fixed-Asset Share With Elevated Turnover
Installed Building Products Inc.
2 interpretationsRevenue Growing With Receivables GrowingLow Fixed-Asset Share With Elevated Turnover